This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Q. Articles by Qian, Q. Search for Related Content PubMed PubMed Citation Articles by Zhang, Q. Articles by Qian, Q.

Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene

¹ Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; ² Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China; ³ Department of Clinical Oncology, University of Hong Kong, Hong Kong, China; and ⁴ Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China

Gene-viral therapy, which uses replication-selective transgene-expressing viruses to manage tumors, can exploit the virtues of gene therapy and virotherapy and overcome the limitations of conventional gene therapy. Using a human telomerase reverse transcriptase-targeted replicative adenovirus as an antiangiogenic gene transfer vector to target new angiogenesis and making use of its unrestrained proliferation are completely new concepts in tumor management. CNHK300-mE is a selective replication transgene-expressing adenovirus constructed to carry mouse endostatin gene therapeutically. Infection with CNHK300-mE was associated with selective replication of the adenovirus and production of mouse endostatin in telomerase-positive cancer cells. Endostatin secreted from a human gastric cell line, SGC-7901, infected with CNHK300-mE was significantly higher than that infected with nonreplicative adenovirus Ad-mE in vitro (800 ± 94.7 ng/ml versus 132.9 ± 9.9 ng/ml) and in vivo (610 ± 42 ng/ml versus 126 ± 13 ng/ml). Embryonic chorioallantoic membrane assay showed that the mouse endostatin secreted by CNHK300-mE inhibited angiogenesis efficiently and also induced distortion of pre-existing vasculature. CNHK300-mE exhibited a superior suppression of xenografts in nude mice compared with CNHK300 and Ad-mE. In summary, we provided a more efficient gene-viral therapy strategy by combining oncolysis with antiangiogenesis.

This article has been cited by other articles:

				J.-X. Wang, Q. Li, and P.-F. Li Apoptosis Repressor with Caspase Recruitment Domain Contributes to Chemotherapy Resistance by Abolishing Mitochondrial Fission Mediated by Dynamin-Related Protein-1 Cancer Res., January 15, 2009; 69(2): 492 - 500. [Abstract] [Full Text] [PDF]

				X. Wang, C. Su, H. Cao, K. Li, J. Chen, L. Jiang, Q. Zhang, X. Wu, X. Jia, Y. Liu, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers Mol. Cancer Ther., June 1, 2008; 7(6): 1598 - 1603. [Abstract] [Full Text] [PDF]

				J. Chen, C. Su, Q. Lu, W. Shi, Q. Zhang, X. Wang, J. Long, Q. Yang, L. Li, X. Jia, et al. Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey Mol. Cancer Ther., June 1, 2008; 7(6): 1562 - 1568. [Abstract] [Full Text] [PDF]

				C. Su, M. Na, J. Chen, X. Wang, Y. Liu, W. Wang, Q. Zhang, L. Li, J. Long, X. Liu, et al. Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy Mol. Cancer Res., April 1, 2008; 6(4): 568 - 575. [Abstract] [Full Text] [PDF]

				Q. Zhang, G. Chen, L. Peng, X. Wang, Y. Yang, C. Liu, W. Shi, C. Su, H. Wu, X. Liu, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res., November 1, 2006; 12(21): 6523 - 6531. [Abstract] [Full Text] [PDF]

				Y. Liu and A. Deisseroth Tumor vascular targeting therapy with viral vectors Blood, April 15, 2006; 107(8): 3027 - 3033. [Abstract] [Full Text] [PDF]

				X. Li, S. P. Raikwar, Y.-H. Liu, S.-J. Lee, Y.-P. Zhang, S. Zhang, L. Cheng, S.-D. Lee, B. E. Juliar, T. A. Gardner, et al. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol. Cancer Ther., March 1, 2006; 5(3): 676 - 684. [Abstract] [Full Text] [PDF]

				T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]